A recent study has shown that MO-I-500 as an FTO inhibitor could significantly reduce the negative effects of streptozotocin-damaged human astrocytoma cells CCF-STTG1 in the AD model [105]. The gene discussed is FTO; the disease is Alzheimer disease.